The Expression and Role of CD30 in Diffuse Large B-cell Lymphoma
CHEN Liling, CUI Dongya, CAI Shaoli*
DLBCL (diffuse large B-cell lymphoma) is a heterogeneous hematologic malignancy, which is the most common type of NHL (non-Hodgkin lymphoma). The incidence rate of DLBCL has been increasing in recent years, which seriously affects people’s health. Studies have found that CD30 is expressed in different degrees in DLBCL, which is closely related to the treatment and prognosis of DLBCL, and it has been identified as an important therapeutic target for DLBCL. In recent years, CD30 targeted therapy has made great progress in the treatment of DLBCL. This article summarizes the research progress of CD30 expression and its role in DLBCL, so as to provide reference for the treatment of DLBCL.
CN
EN